Call for Abstract

International Conference on HIV/AIDS, STDs & STIs, will be organized around the theme “Awareness in Demystifying Silence”

STD-AIDS-2013 is comprised of 15 tracks and 85 sessions designed to offer comprehensive sessions that address current issues in STD-AIDS-2013.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Hepatitis, herpes, and human papilloma viruses
  • Track 1-2Trichomoniasis, syphilis, granuloma inguinale and gonorrhea
  • Track 1-3Chancroid and chlamydia
  • Track 1-4Molecular biology, immunology, and epidemiology of HTLV
  • Track 1-5Reverse sequence syphilis testing: Pros and cons of syphilis screening with EIA
  • Track 1-6STD prevention and statistics: The experience of a health reform state
  • Track 1-7Infectious diseases in low and middle-income countries
  • Track 2-1Systems biology in HIV, METH and cART
  • Track 2-2HIV- diagnosis, retroviral transmission and prevention
  • Track 2-3Mother-to-child transmission of HIV
  • Track 2-4Social, cultural, economic and political issues of sexuality
  • Track 2-5Opportunistic diseases in HIV
  • Track 2-6Nucleoside analogues, and clinical trials in HIV/AIDS
  • Track 2-7Molecular mechanisms and novel targets
  • Track 3-1Classes of drugs and mechanism
  • Track 3-2Immunology and strategies towards HIV and retroviral infections
  • Track 3-3HIV/AIDS and STDs/STIs: Vaccines research and development
  • Track 3-4Nucleoside analogues and molecular mechanisms
  • Track 3-5HIV: Current pharmaceutical design
  • Track 4-1Clinical virology and current research
  • Track 4-2New strategies to combat flu viruses
  • Track 4-3Strain identification assays and rapid diagnostics for viral infections
  • Track 4-4Stem cell therapy for viral infections: Promises and challenges
  • Track 4-5HIV co-infections
  • Track 5-1Virologic challenges at acute HIV Infection
  • Track 5-2Immunologic challenges at acute HIV infection
  • Track 5-3Latent reservoirs of HIV: Perspectives for eradication and development of therapeutic strategies
  • Track 5-4Sexual transmission of HIV-1: Amplification and inhibition
  • Track 6-1Impact of HIV-1 cellular viral load on the progression of HIV-1 disease
  • Track 6-2HIV-DNA in PBMC: A marker for disease progression
  • Track 6-3Quantification of HIV infection and persistence in vivo
  • Track 6-4Evaluation of residual viral replication for optimization of HAART
  • Track 6-5Monocyte subsets and HIV reservoirs in patients on HAART
  • Track 7-1Neuro AIDS research priorities and global efforts
  • Track 7-2Molecular mechanism of differential neuro AIDS by HIV-1B and C clades
  • Track 7-3Alcohol and drugs of abuse interaction with HIV/AIDS, system approach
  • Track 7-4HIV neuropathogenesis
  • Track 7-5Substance-induced behavioral plasticity in the HIV-1 transgenic rat
  • Track 7-6Multi drug, nano-carrier to treat opiate addition and neuro AIDS
  • Track 8-1Genomics and proteomics of HIV and mechanisms of infection
  • Track 8-2HIV infection, lymphocytes, modalities and determinants
  • Track 8-3HIV replication and gene expression
  • Track 8-4Virus-cell interaction pathogenesis
  • Track 8-5Malignancies in HIV, neuropathogenesis and neurological complications
  • Track 8-6Current HIV research
  • Track 9-1Viremia, and blood transfusion safety
  • Track 9-2The case for active virus replication under effective ART
  • Track 9-3Pharmacological cellular sanctuaries in HIV patients
  • Track 9-4The distribution of viral blips amplitudes during HAART
  • Track 9-5Microbicides and HIV
  • Track 10-1New therapeutic approaches
  • Track 10-2Immunotoxins and immune-based therapies for target reservoirs of HIV-infected cells
  • Track 10-3Therapeutic antibodies, gene switches, and enzymes
  • Track 10-4Anti-retroviral therapies and associated complications
  • Track 10-5Qualitative and quantitative, HIV-2 testing, nucleic acid-based tests (NAT)
  • Track 10-6Serologic and nucleic acid amplification
  • Track 10-7Window period, ELISA, western blot, rapid or point-of-care tests
  • Track 10-8HIV testing and counselling
  • Track 11-1HIV/AIDS, STDs, & STIs epidemics across the Globe
  • Track 11-2South, South-East Asia, East Asia and Pacific
  • Track 11-3Latin America and the Caribbean, Eastern Europe and Central Asia
  • Track 11-4Western Europe, North America, and Australasia
  • Track 11-5HIV Virology: Distribution, diversity in world
  • Track 11-6HIV pharmacology and observational studies
  • Track 11-7Current issues and controversies in HIV management
  • Track 11-8Gender inequalities and HIV
  • Track 12-1Sex education, safe sex
  • Track 12-2Strategic use of antiretrovirals
  • Track 12-3Immigration regulation
  • Track 12-4Other strategies in prevention
  • Track 13-1Microbicides for sexually transmitted diseases
  • Track 13-2Pre-exposure prophylaxis
  • Track 13-3Post-exposure prophylaxis
  • Track 13-4Treatment as prevention
  • Track 13-5Problems of drug-drug interaction
  • Track 13-6Drug resistance: NRTI, NNRTI, PI (mechanisms, clinical implications, testing)
  • Track 14-1Latent reservoirs and viral evolution during HAART: The clinical significance of HIV latency
  • Track 14-2Central nervous system and HIV and male genital tract as a viral sanctuary
  • Track 14-3HIV-1 cervico-vaginal reservoir in the era of HAART
  • Track 14-4Viral genomes evolution in tissue reservoirs
  • Track 15-1Family planning providers and FQHCs
  • Track 15-2Essential elements of partnering with FQHCs
  • Track 15-3Emerging research paradigms in STD epidemiology and prevention
  • Track 15-4Bacterial, fungal, viral, and protozoal STDs
  • Track 15-5Ethics, and HIV service delivery